Cross Country Healthcare (CCRN) Stock Forecast, Price Target & Predictions
CCRN Stock Forecast
Cross Country Healthcare stock forecast is as follows: an average price target of $21.00 (represents a 48.31% upside from CCRN’s last price of $14.16) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CCRN Price Target
The average price target for Cross Country Healthcare (CCRN) is $21.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $21.00. This represents a potential 48.31% upside from CCRN's last price of $14.16.
CCRN Analyst Ratings
According to 2 Wall Street analysts, Cross Country Healthcare's rating consensus is 'Buy'. The analyst rating breakdown for CCRN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cross Country Healthcare Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 06, 2024 | Kevin Steinke | Barrington | $21.00 | $16.58 | 26.66% | 48.31% |
The latest Cross Country Healthcare stock forecast, released on May 06, 2024 by Kevin Steinke from Barrington, set a price target of $21.00, which represents a 26.66% increase from the stock price at the time of the forecast ($16.58), and a 48.31% increase from CCRN last price ($14.16).
Cross Country Healthcare Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $21.00 |
| Last Closing Price | $14.16 | $14.16 | $14.16 |
| Upside/Downside | -100.00% | -100.00% | 48.31% |
In the current month, the average price target of Cross Country Healthcare stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cross Country Healthcare's last price of $14.16. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2023 | Credit Suisse | Neutral | Neutral | Hold |
| Jun 13, 2022 | Benchmark | Buy | Buy | Hold |
| Feb 24, 2022 | Benchmark | Buy | Buy | Hold |
Cross Country Healthcare's last stock rating was published by Credit Suisse on Aug 08, 2023. The company gave CCRN a "Neutral" rating, the same as its previous rate.
Cross Country Healthcare Financial Forecast
Cross Country Healthcare Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $622.71M | $628.22M | $636.10M | - | $788.73M | $640.68M | $374.90M | $331.83M | $329.24M | $215.61M | $193.97M | $216.78M | $210.06M | $215.10M | $209.20M |
| Avg Forecast | $349.29M | $338.00M | $333.24M | $327.86M | $339.89M | $330.70M | $324.30M | $319.03M | $319.68M | $310.23M | $334.75M | $374.38M | $404.42M | $443.90M | $531.70M | $594.09M | $594.57M | $617.52M | $740.94M | $745.64M | $615.26M | $320.48M | $306.64M | $289.20M | $196.36M | $174.57M | $198.94M | $210.04M | $208.15M | $202.69M |
| High Forecast | $350.84M | $339.50M | $334.72M | $329.32M | $341.40M | $332.17M | $325.74M | $320.45M | $321.10M | $310.87M | $336.24M | $376.04M | $407.18M | $446.70M | $534.06M | $596.74M | $597.21M | $620.27M | $740.94M | $759.89M | $627.02M | $326.61M | $312.51M | $294.73M | $200.11M | $177.91M | $202.74M | $214.06M | $212.13M | $206.57M |
| Low Forecast | $347.81M | $336.57M | $331.84M | $326.48M | $338.45M | $329.31M | $322.93M | $317.69M | $318.33M | $309.18M | $333.34M | $372.80M | $402.15M | $439.98M | $529.45M | $591.59M | $592.06M | $614.91M | $740.94M | $733.35M | $605.12M | $315.20M | $301.59M | $284.44M | $193.12M | $171.69M | $195.66M | $206.58M | $204.72M | $199.35M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.06% | 1.03% | - | 1.06% | 1.04% | 1.17% | 1.08% | 1.14% | 1.10% | 1.11% | 1.09% | 1.00% | 1.03% | 1.03% |
Cross Country Healthcare's average Quarter revenue forecast for Jun 23 based on 6 analysts is $531.70M, with a low forecast of $529.45M, and a high forecast of $534.06M. CCRN's average Quarter revenue forecast represents a -14.61% decrease compared to the company's last Quarter revenue of $622.71M (Mar 23).
Cross Country Healthcare EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $24.71M | $37.89M | $55.17M | $57.99M | $63.36M | - | $97.99M | $78.84M | $29.50M | $18.30M | $23.28M | $7.33M | $2.69M | $-9.86M | $2.25M | $4.42M | $1.27M |
| Avg Forecast | $23.23M | $22.48M | $22.16M | $21.80M | $22.60M | $21.99M | $21.57M | $21.22M | $21.26M | $20.63M | $22.26M | $79.33M | $26.90M | $29.52M | $35.36M | $72.12M | $39.54M | $35.55M | $49.28M | $65.57M | $68.66M | $28.10M | $15.10M | $14.58M | $6.76M | $14.53M | $-65.06M | $3.04M | $13.84M | $3.43M |
| High Forecast | $23.33M | $22.58M | $22.26M | $21.90M | $22.71M | $22.09M | $21.66M | $21.31M | $21.36M | $20.67M | $22.36M | $95.20M | $27.08M | $29.71M | $35.52M | $86.55M | $39.72M | $42.66M | $49.28M | $78.68M | $82.40M | $33.72M | $18.12M | $17.50M | $8.11M | $17.43M | $-52.04M | $3.65M | $14.11M | $4.12M |
| Low Forecast | $23.13M | $22.38M | $22.07M | $21.71M | $22.51M | $21.90M | $21.48M | $21.13M | $21.17M | $20.56M | $22.17M | $63.47M | $26.75M | $29.26M | $35.21M | $57.70M | $39.38M | $28.44M | $49.28M | $52.45M | $54.93M | $22.48M | $12.08M | $11.67M | $5.41M | $11.62M | $-78.07M | $2.43M | $13.62M | $2.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 1.07% | 0.77% | 1.47% | 1.78% | - | 1.49% | 1.15% | 1.05% | 1.21% | 1.60% | 1.08% | 0.19% | 0.15% | 0.74% | 0.32% | 0.37% |
5 analysts predict CCRN's average Quarter EBITDA for Dec 23 to be $26.90M, with a high of $27.08M and a low of $26.75M. This is 8.85% upper than Cross Country Healthcare's previous annual EBITDA (Sep 23) of $24.71M.
Cross Country Healthcare Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.81M | $21.34M | $29.44M | $38.79M | $34.79M | - | $61.98M | $77.57M | $23.43M | $11.55M | $19.45M | $4.61M | $-1.33M | $-14.15M | $-2.09M | $-1.14M | $-3.13M |
| Avg Forecast | $7.92M | $7.32M | $6.92M | $5.48M | $7.11M | $6.20M | $5.30M | $4.39M | $4.42M | $3.24M | $4.51M | $52.67M | $9.31M | $13.80M | $20.68M | $47.88M | $30.37M | $28.23M | $46.71M | $43.53M | $67.56M | $22.32M | $9.53M | $12.18M | $4.25M | $-7.20M | $-93.40M | $-2.82M | $2.03M | $-8.45M |
| High Forecast | $7.97M | $7.36M | $6.96M | $5.51M | $7.15M | $6.23M | $5.33M | $4.42M | $4.45M | $3.26M | $4.54M | $63.21M | $10.35M | $14.47M | $20.80M | $57.46M | $30.55M | $33.88M | $46.71M | $52.24M | $81.08M | $26.78M | $11.43M | $14.62M | $5.11M | $-5.76M | $-74.72M | $-2.26M | $2.08M | $-6.76M |
| Low Forecast | $7.88M | $7.28M | $6.88M | $5.45M | $7.07M | $6.16M | $5.27M | $4.37M | $4.40M | $2.92M | $4.49M | $42.14M | $8.62M | $13.13M | $20.57M | $38.31M | $30.20M | $22.59M | $46.71M | $34.82M | $54.05M | $17.86M | $7.62M | $9.74M | $3.40M | $-8.64M | $-112.08M | $-3.38M | $1.99M | $-10.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 1.03% | 0.61% | 1.28% | 1.23% | - | 1.42% | 1.15% | 1.05% | 1.21% | 1.60% | 1.08% | 0.19% | 0.15% | 0.74% | -0.56% | 0.37% |
Cross Country Healthcare's average Quarter net income forecast for Dec 23 is $9.31M, with a range of $8.62M to $10.35M. CCRN's average Quarter net income forecast represents a -27.30% decrease compared to the company's last Quarter net income of $12.81M (Sep 23).
Cross Country Healthcare SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $69.63M | $78.94M | $84.26M | $81.17M | $80.22M | - | $76.81M | $65.77M | $52.85M | $50.34M | $46.33M | $44.87M | $40.80M | $42.25M | $45.88M | $45.57M | $44.41M |
| Avg Forecast | $57.91M | $56.04M | $55.25M | $54.36M | $56.35M | $54.83M | $53.77M | $52.89M | $53.00M | $51.43M | $55.50M | $65.27M | $67.05M | $73.60M | $88.15M | $59.34M | $98.57M | $63.68M | $122.84M | $53.95M | $57.29M | $50.34M | $41.53M | $29.01M | $41.40M | $28.94M | $32.98M | $61.94M | $34.51M | $119.90M |
| High Forecast | $58.17M | $56.29M | $55.49M | $54.60M | $56.60M | $55.07M | $54.01M | $53.13M | $53.24M | $51.54M | $55.75M | $78.33M | $67.51M | $74.06M | $88.54M | $71.21M | $99.01M | $76.41M | $122.84M | $64.73M | $68.74M | $60.40M | $49.84M | $34.82M | $49.67M | $29.50M | $33.61M | $74.33M | $35.17M | $143.88M |
| Low Forecast | $57.66M | $55.80M | $55.02M | $54.13M | $56.11M | $54.60M | $53.54M | $52.67M | $52.78M | $51.26M | $55.27M | $52.22M | $66.67M | $72.95M | $87.78M | $47.47M | $98.16M | $50.94M | $122.84M | $43.16M | $45.83M | $40.27M | $33.23M | $23.21M | $33.12M | $28.47M | $32.44M | $49.55M | $33.94M | $95.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 0.90% | 1.42% | 0.82% | 1.26% | - | 1.42% | 1.15% | 1.05% | 1.21% | 1.60% | 1.08% | 1.41% | 1.28% | 0.74% | 1.32% | 0.37% |
Cross Country Healthcare's average Quarter SG&A projection for Dec 23 is $67.05M, based on 5 Wall Street analysts, with a range of $66.67M to $67.51M. The forecast indicates a -3.70% fall compared to CCRN last annual SG&A of $69.63M (Sep 23).
Cross Country Healthcare EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.37 | $0.60 | $0.82 | $1.06 | $0.94 | - | $1.67 | $2.10 | $0.63 | $0.32 | $0.54 | $0.13 | $-0.04 | $-0.39 | $-0.06 | $-0.03 | $-0.09 |
| Avg Forecast | $0.23 | $0.22 | $0.20 | $0.16 | $0.21 | $0.18 | $0.16 | $0.13 | $0.13 | $0.10 | $0.13 | $0.17 | $0.27 | $0.41 | $0.61 | $0.75 | $0.89 | $0.95 | $1.35 | $1.41 | $1.24 | $0.34 | $0.36 | $0.34 | $0.09 | $-0.03 | $-0.03 | $-0.01 | $0.06 | $0.01 |
| High Forecast | $0.23 | $0.22 | $0.20 | $0.16 | $0.21 | $0.18 | $0.16 | $0.13 | $0.13 | $0.10 | $0.13 | $0.17 | $0.30 | $0.43 | $0.61 | $0.76 | $0.90 | $0.96 | $1.35 | $1.45 | $1.27 | $0.35 | $0.37 | $0.35 | $0.09 | $-0.03 | $-0.03 | $-0.01 | $0.06 | $0.01 |
| Low Forecast | $0.23 | $0.21 | $0.20 | $0.16 | $0.21 | $0.18 | $0.16 | $0.13 | $0.13 | $0.09 | $0.13 | $0.17 | $0.25 | $0.39 | $0.61 | $0.75 | $0.89 | $0.95 | $1.35 | $1.38 | $1.22 | $0.33 | $0.36 | $0.33 | $0.08 | $-0.03 | $-0.03 | $-0.01 | $0.06 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.99% | 1.09% | 1.19% | 0.99% | - | 1.18% | 1.69% | 1.85% | 0.88% | 1.58% | 1.51% | 1.33% | 11.93% | 4.83% | -0.51% | -7.00% |
According to 5 Wall Street analysts, Cross Country Healthcare's projected average Quarter EPS for Dec 23 is $0.27, with a low estimate of $0.25 and a high estimate of $0.30. This represents a -25.87% decrease compared to CCRN previous annual EPS of $0.37 (Sep 23).
Cross Country Healthcare Peer Comparison by Price Target
CCRN Forecast FAQ
Is Cross Country Healthcare a good buy?
Yes, according to 2 Wall Street analysts, Cross Country Healthcare (CCRN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of CCRN's total ratings.
What is CCRN's price target?
Cross Country Healthcare (CCRN) average price target is $21 with a range of $21 to $21, implying a 48.31% from its last price of $14.16. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cross Country Healthcare stock go up soon?
According to Wall Street analysts' prediction for CCRN stock, the company can go up by 48.31% (from the last price of $14.16 to the average price target of $21), up by 48.31% based on the highest stock price target, and up by 48.31% based on the lowest stock price target.
Can Cross Country Healthcare stock reach $20?
CCRN's average twelve months analyst stock price target of $21 supports the claim that Cross Country Healthcare can reach $20 in the near future.
What are Cross Country Healthcare's analysts' financial forecasts?
Cross Country Healthcare's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.31B (high $1.32B, low $1.31B), average EBITDA is $87.38M (high $87.77M, low $87.01M), average net income is $23M (high $23.14M, low $22.88M), average SG&A $217.84M (high $218.81M, low $216.92M), and average EPS is $0.677 (high $0.681, low $0.674). CCRN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.35B (high $1.35B, low $1.34B), average EBITDA is $89.68M (high $90.07M, low $89.3M), average net income is $27.64M (high $27.8M, low $27.49M), average SG&A $223.55M (high $224.55M, low $222.61M), and average EPS is $0.814 (high $0.819, low $0.809).
Did the CCRN's actual financial results beat the analysts' financial forecasts?
Based on Cross Country Healthcare's last annual report (Dec 2022), the company's revenue was $2.81B, beating the average analysts forecast of $2.7B by 4.00%. Apple's EBITDA was $304.81M, beating the average prediction of $189.93M by 60.49%. The company's net income was $188.46M, beating the average estimation of $148.84M by 26.62%. Apple's SG&A was $324.21M, missing the average forecast of $339.04M by -4.37%. Lastly, the company's EPS was $5.09, beating the average prediction of $4.61 by 10.41%. In terms of the last quarterly report (Mar 2023), Cross Country Healthcare's revenue was $622.71M, beating the average analysts' forecast of $594.09M by 4.82%. The company's EBITDA was $55.18M, missing the average prediction of $72.12M by -23.50%. Cross Country Healthcare's net income was $29.44M, missing the average estimation of $47.88M by -38.53%. The company's SG&A was $84.26M, beating the average forecast of $59.34M by 42.00%. Lastly, the company's EPS was $0.82, beating the average prediction of $0.751 by 9.16%